Healthy pipeline in CLL, report reveals

12 July 2024

The clinical trial landscape for chronic lymphocytic leukemia (CLL) shows a robust global effort to advance treatment options and understand the disease, according to a report.

Contract research organization Novotech has published the research report, entitled Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trial Landscape.

The report reveals that, since 2019, more than 1,000 clinical trials have been started worldwide, with North America leading at 37% of these studies, followed closely by the Asia-Pacific region at 34%, Europe at 20%, and the rest of the world with 8%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology